The N-Lorem Foundation is Developing Treatments for Patients With Ultra-Rare Diseases
source: pixabay.com

The N-Lorem Foundation is Developing Treatments for Patients With Ultra-Rare Diseases

  A recent article in the Encinitas Advocate heralded the dedication of Stan Crooke, n-Lorem Foundation’s CEO and founder. The nonprofit Foundation’s team acts as middlemen, working with patients who…

Continue Reading The N-Lorem Foundation is Developing Treatments for Patients With Ultra-Rare Diseases
New $15M Effort to Expand ALS Research and Find Biomarkers
https://pixabay.com/en/dollar-money-currency-trade-1974694/

New $15M Effort to Expand ALS Research and Find Biomarkers

Target ALS has recently launched a new research initiative, in which they will dedicate $15 million to amyotrophic lateral sclerosis (ALS) research, specifically the discovery of biomarkers. These millions will…

Continue Reading New $15M Effort to Expand ALS Research and Find Biomarkers
Brainstorm Shares the Results of its Phase 3 Study of NurOwn to Treat ALS
source: pixabay.com

Brainstorm Shares the Results of its Phase 3 Study of NurOwn to Treat ALS

  According to a report in BioPharma Dive, Brainstorm Therapeutics, a New York biotechnology company, said that while its NurOwn therapy for amyotrophic lateral sclerosis (ALS) appeared to have a…

Continue Reading Brainstorm Shares the Results of its Phase 3 Study of NurOwn to Treat ALS
New Discovery Allows Researchers to Study Mechanisms in Neurodegenerative Diseases from Beginning of life
source: pixabay.com

New Discovery Allows Researchers to Study Mechanisms in Neurodegenerative Diseases from Beginning of life

Dilated cardiomyopathy is a heart condition caused by a mutation in the RBM20 gene. This heart condition is unique because it can affect young adults. These individuals are at an…

Continue Reading New Discovery Allows Researchers to Study Mechanisms in Neurodegenerative Diseases from Beginning of life

Scientists Have Discovered An Immune Cell That May Partially Reverse Damage Caused by ALS and MS

A series of articles recently published in FierceBiotech describe a discovery by Ohio State and Michigan University scientists. The teams have discovered an immune cell that could be tapped to…

Continue Reading Scientists Have Discovered An Immune Cell That May Partially Reverse Damage Caused by ALS and MS

New Collaboration: Scribe Therapeutics and Biogen to Explore CRISPR-Related Therapies for ALS

On October 6, 2020, molecular engineering company Scribe Therapeutics announced an exciting partnership. Originally founded by molecular engineers and CRISPR inventors, Scribe Therapeutics seeks to develop in vivo genetic medicine to treat…

Continue Reading New Collaboration: Scribe Therapeutics and Biogen to Explore CRISPR-Related Therapies for ALS
FDA Accepts Priority Review NDA for Potential Niemann-Pick Disease Type C Drug
source: pixabay.com

FDA Accepts Priority Review NDA for Potential Niemann-Pick Disease Type C Drug

According to a story from globenewswire.com, the US Food and Drug Administration (FDA) recently accepted the New Drug Application (NDA) for arimoclomol. This application is for the use of the…

Continue Reading FDA Accepts Priority Review NDA for Potential Niemann-Pick Disease Type C Drug
Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete
source: pixabay.com

Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete

According to a story from BioSpace, the biopharmaceutical company Clene Nanomedicine, Inc., has recently announced that it has completed the process of enrollment patient participants in its upcoming phase 2…

Continue Reading Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete

Researchers at Nagoya University are One Step Closer to Unraveling the Tau Mystery in Neurodegenerative Diseases

According to a recent article in MedicalXpress, researchers in Japan led by Dr. Shinsuke Ishigaki and his team at Nagoya University, have identified new molecular details about tau’s activity. Alzheimer’s,…

Continue Reading Researchers at Nagoya University are One Step Closer to Unraveling the Tau Mystery in Neurodegenerative Diseases
Preclinical Data Supports NurOwn for ALS, MS, and Alzheimer’s Disease
Source: Pixabay

Preclinical Data Supports NurOwn for ALS, MS, and Alzheimer’s Disease

  Within the last month, BrainStorm Cell Therapeutics Inc. announced the publication of pre-clinical data on the NurOwn system. NurOwn technology produces autologous, bone marrow-derived mesenchymal stem cells (MSCs) for…

Continue Reading Preclinical Data Supports NurOwn for ALS, MS, and Alzheimer’s Disease

Editor’s Choice: Experimental Trial for ALS and New Insights on COVID-19

Happy Friday! We're about halfway through Stevens-Johnson Syndrome Awareness Month. It's a type of severe skin reaction that often involves admission to a burn unit for treatment. Looking for ways…

Continue Reading Editor’s Choice: Experimental Trial for ALS and New Insights on COVID-19
Study: Verdiperstat as a Treatment for Amyotrophic Lateral Sclerosis (ALS)
source: pixabay.com

Study: Verdiperstat as a Treatment for Amyotrophic Lateral Sclerosis (ALS)

The HEALY ALS Platform Trial, being conducted by Biohaven Pharma, has begun enrolling patients. This study is intended to test the efficacy of three treatments on amyotrophic lateral sclerosis (ALS),…

Continue Reading Study: Verdiperstat as a Treatment for Amyotrophic Lateral Sclerosis (ALS)
Scientists Can Identify Schwann Cells Using Novel Bar Code Technique
Image by Markus Spiske from Pixabay

Scientists Can Identify Schwann Cells Using Novel Bar Code Technique

Scientists and researchers have long known how important glial cells are to the nervous system. Not only do these cells make up a majority of cells within the central nervous…

Continue Reading Scientists Can Identify Schwann Cells Using Novel Bar Code Technique
New Drug Application for Niemann-Pick Disease Type C Treatment Submitted Under Rolling Review
source: pixabay.com

New Drug Application for Niemann-Pick Disease Type C Treatment Submitted Under Rolling Review

According to a story from globenewswire.com, the biopharmaceutical company Orphazyme A/S has recently announced that it has submitted its New Drug Application (NDA) for its experimental treatment arimoclomol to the…

Continue Reading New Drug Application for Niemann-Pick Disease Type C Treatment Submitted Under Rolling Review
Arimoclomol Receives the Fast Track Designation for the Treatment of ALS
source: pixabay.com

Arimoclomol Receives the Fast Track Designation for the Treatment of ALS

CytRx Corporation has recently received the Fast Track designation for their ALS treatment, arimoclomol. This status was also given for the treatment of Niemann-Pick disease and sporadic Inclusion Body Myositis…

Continue Reading Arimoclomol Receives the Fast Track Designation for the Treatment of ALS
Exploring the Similar Pathology “Genetic Doppelgängers” ALS and SCA36
Thor_Deichmann / Pixabay

Exploring the Similar Pathology “Genetic Doppelgängers” ALS and SCA36

Recently, scientists from Emory University set out to discover whether there was any pathological link between spinocerebellar ataxia type 36 (SCA36) and amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD). Both…

Continue Reading Exploring the Similar Pathology “Genetic Doppelgängers” ALS and SCA36
Could Biobots be the Key to Understanding ALS and other Neuromuscular Diseases?
source: pixabay.com

Could Biobots be the Key to Understanding ALS and other Neuromuscular Diseases?

  Biological robots, commonly known as biobots, mimic the actions of other organisms (e.g. jumping or swimming). Biobots are composed of artificial materials and also organic material. As published in…

Continue Reading Could Biobots be the Key to Understanding ALS and other Neuromuscular Diseases?
New Therapy for ALS and Other Neurodegenerative Diseases
geralt / Pixabay

New Therapy for ALS and Other Neurodegenerative Diseases

ProMIS Neurosciences is a biotechnology company that works specifically with antibody treatments, and they have recently developed intrabodies for the treatment of amyotrophic lateral sclerosis (ALS). This same therapy has…

Continue Reading New Therapy for ALS and Other Neurodegenerative Diseases